-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $25 Price Target

Benzinga·06/03/2026 16:13:36
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Kyverna Therapeutics (NASDAQ:KYTX) with a Buy and maintains $25 price target.